Viral Clearance Market Overview and Introduction

Viral Clearance Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030. The global viral clearance market is estimated to be over US$ 200 Mn in 2017.It is anticipated to grow at a CAGR of 21.0% from 2019 to 2030.

The threat of contamination of biological products, namely vaccines, bio therapeutics and biologics is a major source of concern for laboratories, pharmaceutical companies and other research & educational establishments. Such contaminations may arise as a result of chemical impurities, fungi, bacteria and viruses. The occurrence of viral contamination affects the raw materials, cell culture, bioreactors and several downstream processes. Therefore, practicing virus safety and viral clearance studies is extremely pivotal in the process of manufacturing as well as research studies.

Rapid growth in the demand for biopharmaceutical products is a major contributing factor contributing to the growth of the global viral clearance market. The ability of biotherapeutics to treat diseases and ailments and not merely its symptoms with high efficacy and minimal side effects has been crucial in continual adoption of such products. Moreover, increasing investments in the sector of R&D coupled with rising incidences of chronic disorders worldwide is anticipated to present a lucrative scenario for the extensive growth of this market. However, high associated costs and time intensive pipeline development process is likely to restrain the market to a certain extent.

Viral Clearance Market by Method

On the basis of method, the viral clearance Industry is segmented into viral removal, and viral inactivation. Viral removal segment can further classified into nanofiltration, chromatography, and precipitation. Whereas, the segment of viral inactivation can be additionally divided into solvent detergent method, low pH, pasteurization and other methods of viral inactivation. In terms of revenue, the viral removal segment is anticipated to account for the largest share of the global viral clearance market. The growth of the segment can be attributed to the increasing R&D activities from both private and public sectors.

Viral Clearance Market by Application

Similarly the segment of applications is classified into blood & blood products, recombinant proteins, vaccines and other applications. The segment of other applications is estimated to account for the largest share of the viral clearance market, owing to the increasing awareness regarding stem cell therapies, tissue-based therapies and other treatments for several diseases.

Viral Clearance Market by End Users

On the basis of end user the viral clearance market can be distinctly segmented into pharmaceutical & biotechnology companies, academic research institutes, contract research organizations and others. Rising outsourcing for services related to drug discovery and extensive development of infrastructure of drug discovery is estimated to contribute significantly to the dominant market share of contract research organizations segment.

Viral Clearance Market by Regions

The global viral clearance Industry can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of virus clearance, followed by Europe and Asia Pacific. North America will continue to dominate the global viral clearance market in the forecast period owing to factors such as highly developed healthcare system and presence of private and public funding in the sector of R&D. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered at China, India, and Japan. Factors such as the rising focus of major players in emerging Asian countries and government support are driving the growth of the viral clearance market in this region.

Viral Clearance Market Prominent Players

The prominent players in the global viral clearance market are VIRUSURE, BSL Bioservice, Texcell, Vironova , Kedrion S.p.A , Charles River, Merck KGaA, WuXi Biologics, Lonza, and Avance Biosciences